Category Archives: Myocardial Infarction

This article was originally published here JCI Insight. 2020 Oct 22:142534. doi: 10.1172/jci.insight.142534. Continue reading →

This article was originally published here Circ Cardiovasc Interv. 2020 Oct 27:CIRCINTERVENTIONS120009314 Continue reading →

This article was originally published here J Am Heart Assoc. Continue reading →

In severely obese patients with previous myocardial infarction (MI), metabolic surgery (Roux-en-Y gastric bypass or sleeve gastrectomy) was associated with a lower risk of heart attack and new onset heart failure, according to study results published in Circulation. Not only are obese individuals nearly 6 times more likely to develop type 2 diabetes (T2D), severe obesity now puts those with coronavirus disease 2019 (COVID-19) at a high risk of death. With the increasing prevalence of obesity there is an expected increase in obese patients with T2D and cardiovascular disease (CVD), the authors wrote. Continue reading →

This article was originally published here Mol Biol Rep. 2020 Oct 26. doi: 10.1007/s11033-020-05877-7. Continue reading →

Application seeks approval of XARELTO plus aspirin to reduce the risk of major thrombotic vascular events in patients after lower-extremity revascularization due to symptomatic peripheral artery disease (PAD) XARELTO is currently approved to reduce the risk of major cardiovascular events, like heart attack and stroke, in people with chronic PAD An estimated 20 million Americans are living with PAD, a disease often underdiagnosed and undertreated RARITAN, N.J.,Oct. Continue reading →

A supplemental New Drug Application (sNDA) for rivaroxaban (Xarelto; Janssen) to reduce the risk of major thrombotic vascular events in patients with peripheral artery disease (PAD) has been submitted to the Food and Drug Administration (FDA). The application is supported by data from the double-blind, placebo-controlled phase 3 VOYAGER PAD trial that assessed the efficacy and safety of rivaroxaban, a Factor Xa inhibitor, in 6564 patients aged 50 years and older with symptomatic PAD after lower extremity revascularization procedures Continue reading →

JAMA Netw Open. 2020 Oct 1;3(10):e2021182. Continue reading →

Background:Coronary artery disease (CAD) is a significant risk factor for atrial fibrillation (AF). Experimental studies demonstrated that atrial ischemia induced by right coronary artery (RCA) stenosis promote AF triggers and development of electro-anatomical substrate for AF. Continue reading →

The Myocardial Infarction Drug Market report includes overview, which interprets value chain structure, industrial environment, regional analysis, applications, market size, and forecast. This is a latest report, covering the current COVID-19 impact on the market. The pandemic of Coronavirus (COVID-19) has affected every aspect of life globally Continue reading →